MTOR and Nephroblastoma: The lack of therapeutic efficacy of U0126 in this Wilms tumor model and only a transient decrease of glucolytic activity could be explained, at least in part, by continuing IGF2-induced signaling from IGF1R through the PI3K-AKT-mTOR pathway [45], bypassing the block in MAPK signaling.